Cellgen Diagnostics is an early stage venture that is developing a break through Companion Diagnostic platform that will enable Precision Medicine by determining whether a patients genetic profile is a match for the prescribed cancer therapeutic.

1. Bringing Companion Diagnostics into the Clinic
Enabling Precision Medicine

2. 2
Cellgen is developing a bio-fluid based molecular diagnostic that
will serve as a cancer therapeutic guidance platform capable of
pushing companion diagnostic testing from reference labs into
clinics
Headquartered in Irvine, CA with an RD lab in San Diego
Technology exclusively licensed from UC San Diego
Founded in October of 2012
Technology transfer completed in June 2015
Lean organization with 2 full-time and 2 part-time employees
Overview

3. 3
Management Team Key Advisors
Lavance Northington, MBA
Chief Executive Officer
Has successfully led several start-ups; Most
recently served as Founding President of
Soberlink
John Radak, CPA MBA
Financial Strategic Advisor
Former VP of Finance Accounting of Life
Technologies; Former CFO of Quidel; Current CFO
of ArborGen
Gary Gust
Technology Officer
Previously held senior positions at Johnson
Johnson and GenMark Diagnostics; Taken more
than a dozen devices through FDA approval
Robert Thompson
Strategic Advisor
Former CEO of e-Screen (sold to Alere); Current
CEO of Emerge Diagnostics
Yuhwa Lo, Ph.D.
Cellgen Technology Inventor
Professor of electrical and computer engineering
at University of California, San Diego; Director of
Nano3 and Calit2; Transferred over 15 different
technologies out of his lab
Sylvia Norman, Ph.D.
Scientific Officer
Previously held senior positions at Gen-Probe and
DermTech
Alex Khalessi. M.D.
Medical Advisor
Director of Endovascular Neurosurgery at
University of California, San Diego

4. 4
Investment Opportunity
$775k investment to date
»» 2009-13: $550K of non-dilutive
grants in conjunction with UCSD
»» 9/2012: $100k ($2M pre-money)
»» 5/2013: $175k ($2M pre-money)
»» 5/2015: $500k ($3.8M pre-money)
Capital Efficient
»» Successfully transferred
technology from UCSD
»» Opened its RD lab in San Diego
»» Developed its LDT workflow
and commenced discovery
on its POCT platform
Use of proceeds
»» Certify CLIA lab and gain CAP
accreditation
»» Develop an alpha prototype of its
clinical EVAP platform
»» Hire additional technical
commercial professionals
»» Provide 12 months of runway until
its Series A round
(planned for 2Q 2017)
$775K
Cellgen is raising a $1M follow-on seed round with
»» a $10M pre-money valuation based on discounted cash flow and comparable company analyses (See MedDx Industry
Sector Analysis); and
»» a capital efficient business leveraging proven biology to lower overall investment risk

5. 5
Valuation Drivers
Cellgen embodies several of the prevailing trends currently impacting
clinical diagnostics
»» Multiple product roadmap
»» Strategic appeal for acquisition
»» Recognition that companion diagnostics are an essential element of personalized medicine
»» Companion diagnostics are key to sustainable cost containment
»» Migration of diagnostics to the point-of-care
Large strategics are following these trends closely as
evidenced in their corporate development initiatives
(acquisitions, partnering etc.)

6. 6
Significant Value Creation
$450M $450M$203M $308M$275M
Main Driver:
Novel POCT
MDx Platform
Main Driver:
Novel MDx
Platform
Main Driver:
Novel Digital
PCR Platform
Main Driver:
Novel Protein
Research Tool
Main Driver:
Novel MDx
Platform
Targets capable of hitting key inflection points (technology
validation FDA approval) will continue to receive much
attention and premium valuations from potential acquirers with
the potential to create immense value for shareholders

7. 7
What Does Cellgen Sell?
Cellgen is developing a biofluid based, molecular diagnostic
platform that uses disposable cartridges to determine if a
patients genetic profile is a match for a particular cancer
therapeutic

8. 8
What Makes Cellgen Different: Novel EVAP Technology
Clearly Disruptive
Based on patent-pending evaporating droplet
technology
»» Amplification-free
»» Target flexibility: DNA including cfDNA, RNA
including exosomal miRNA proteins
»» Quantitative, digital results in less than 5 hours
»» Target enrichment up to 500X
»» On-chip hybridization and detection
Great promise for near-patient testing
Tecnolology System Cost Sample Type Technology Strengths Test Run Time Test Location Reimbursement
Cellgen Liquid
Biopsy CDx
$15K-$20K Bio Fluids
Evaporation/
Hybridization
Speed, Cost, Ease
of Use, Desktop
Footprint
4-5 hours Clinic Physician
Traditional Liquid
Biopsy CDx
$75K-$100K Bio Fluids PCR/ NGS
No Need for
Tissue Biopsy
7-10 days Reference Lab Reference Lab
Tissue Biopsy CDx $75K-$100K Tissue
PCR/ NGS/ FISH/
IHC
Industry “Gold
Standard”
Universally
Accepted
7-10 days Reference Lab Reference Lab
AMPLIFICATION

9. 9
Cellgen’s Patent Pending Process
Pipetting DNA mixed with
buffer onto black silicone
chip with super-hydrophobic
surface and hydrophilic
micro islands
Sample Pipetting

10. 10
Manual Workflow: Condense DNA on Micro Island Wells
Begin heating
Evaporating
Completely dried

11. 11
Manual Workflow: Re-Suspension
Dipping in hybridization solution, creating homogenous nano-droplets throughout
the entire chip
Dip in hybridization solution to enrich
target up to 1 million times

12. 12
Manual Workflow: Oil Immersion
Immerse the chip
into the oil to
create a controlled
hybridization
chamber for the
self-assembled
droplets
Oil
Oil

13. 13
Manual Workflow: Hybridization in Controlled Temperature

14. 14
Manual Workflow: Washing
Submerge the chip into washing solution to wash away all un-hybridized DNAs and
Q-dots

15. 15
Manual Workflow: Observation Under Microscope
Wafer Chip
Washing allows for the detection of individual binding events of each target DNA
marker

16. 16
Manual Workflow: DNA Molecules Under the Microscope
Q-dot emission from target DNA (green) and non-specific binding or imperfect
wash (red) in high DNA copy number (left) and low DNA copy number (right).
The target DNA is the number of green spots subtracted from the number of
red spots.

17. 17
The Problem: Current Therapies Fail Most Patients
“HEALTH CARE TODAY IS IN CRISIS AS IT IS EXPENSIVE, REACTIVE,
INEFFICIENT, AND FOCUSED LARGELY ON ONE-SIZE-FITS-ALL
TREATMENTS FOR EVENTS OF LATE STAGE DISEASE.”
—Ralph Snyderman, M.D., Chancellor Emeritus, Duke University
IMPRECISION MEDICINE
Abilify
aripiprazole
(Schizophrenia)
Advair Diskus
fluticasone propionate
(Asthma)
Nexium
esomeprazole
(Heartburn)
Enbrel
etanercept
(Psoriasis)
Humira
adalimumab
(Arthritis)
Remicade
infliximab
(Crohn’s disease)
Crestor
rosuvastatin
(High cholesterol)
Copaxone
glatiramer acetate
(Multiple sclerosis)
Cymbalta
duloxetine
(Depression)
Neulasta
pegfilgrastim
(Neurtopenia)
For every person they do help (blue), the ten highest-grossing drugs in the
United States fail to help most patients (red). Successfully helped Unsuccessfully helped
$350BEstimated Healthcare
Spend Wasted in 2011
Over

18. 18
The Solution: Personalized Medicine
The right person, the right drug at the right time
Medicine Today
Reactive
Population-based
One-size-fits-all model of care
Personalized Medicine
Predictive
Preventive
Patient-centric model of care
Patients with unknown
disease sub-group
Unlikely to Respond
or Adverse Reaction
Likely to Respond
A
B
On Time,
Everytime
Genetic Match

19. 19
Key Statistics
42 percent of all drugs in the pipeline have a companion diagnostic
Oncology leads the way with 73 percent of the pipeline represented by personalized therapies
Biopharmaceutical companies nearly doubled their RD investment in personalized medicines over the
past five years, and expect to increase their investment by an additional one-third in the next five years
Biopharmaceutical researchers forecast a 69 percent increase in the number of personalized medicines
in development over the next five years.
Personalized Medicine: At Its Tipping Point
Personalized Medicine is Transforming Cancer Care
73% of Cancer medicines
in the pipline have
the potential to be
personalized medicines
Biopharmaceutical companies focusing on personalized medicine has resulted in several recent approvals and a
growing number of new medicines in the pipeline
“ONCOLOGY IS ON FIRE WITH
[PERSONALIZED MEDICINE], WITH
TREATMENT SELECTIONS BASED
ON INDIVIDUAL MOLECULAR
CHARACTERISTICS. THIS IS ALSO
HAPPENING WITH CHRONIC
INFECTIOUS DISEASES, AND GENETIC
DISEASES ARE NOT FAR BEHIND”
—Janet Woodcock, Director
Center for Drug Evaluation and Research,
U.S. Food and Drug Administration

20. 20
Personalized Medicine: Stakeholders Perfectly Aligned
Rx Company Benefits
Accelerated FDA approvals
Faster therapeutic adoption
Decreased development costs
Accelerated clinical trials cost
Longer product life cycles
Patient Benefits
Better outcomes
Reduced trial and error prescribing
Avoid adverse drug reactions
Avoid over toxicity
“IN ORDER FOR ANY OF OUR DRUGS TO MOVE INTO CLINICAL DEVELOPMENT, THERE MUST
BE A BIOMARKER PLAN … TO DETERMINE WHICH BIOMARKERS CAN BE USED IN CLINICAL
DEVELOPMENT TO AID IN DECISION MAKING OR TO HELP IN PATIENT SELECTION”
—Nancy Simonian, MD
Chief Medical Officer, Millenium Pharmaceuticals
Physician Benefits
Assay reimbursement
New revenue center
Reduced lab sendouts
Faster clinical decisions
Payer Benefits
Fewer unsubstantiated payouts
Meaningful use initiatives meet
Substantial financial savings
Less over-prescribing of drugs

21. 21
Companion Diagnostics are the Key to Personalized Medicine
“IN MOST CIRCUMSTANCES, IF USE OF AN IN VITRO COMPANION DIAGNOSTIC DEVICE IS ESSENTIAL FOR THE
SAFE AND EFFECTIVE USE OF A THERAPEUTIC PRODUCT, THE IVD COMPANION DIAGNOSTIC DEVICE AND
THERAPEUTIC PRODUCT SHOULD BE APPROVED OR CLEARED CONTEMPORANEOUSLY BY FDA FOR THE USE
INDICATED IN THE THERAPEUTIC PRODUCT LABELING”
—FDA
CDx
Companion diagnostics enable personalized medicine by
analyzing a patient’s DNA to determine if their genetics are a
match for a given drug

22. 22
Current Companion Diagnostics Landscape
Current CDx tests are specialized kits which run on
complex technology platforms and are focused on a
specific target type (DNA, RNA, Proteins)
Consequently, all CDx testing is currently performed
away from patients in reference and specialty labs
preventing patients and clinicians from quickly
receiving valuable information
Even when a companion diagnostic is unequivocally required in drug labeling, not all doctors order testing for a variety of
reasons, including lengthy turnaround times for results and difficulty getting a tumor sample.
— GenomeWeb - February 2016
Current: 1-2 Weeks Average Turnaround Times

23. 23
Cellgen Diagnostics: Changing the Companion Diagnostics Landscape
Physicians and patients
receive vital information
rapidly to avoid wasting
precious time
Cellgen: CDx Performed in the Clinic, Results in Hours
Greatly improve patient outcomes by eliminating delays in
therapy selection, improving turnaround time from days to
hours
Creates a significant new revenue opportunity
for physicians
Drives increased commercial adoption of therapeutics,
particularly those from smaller Rx companies
Incorporates machine learning to dynamically improve
prediction of therapeutic response
Cellgen’s EVAP platform will be capable of performing near-patient CDx assays, while at the same time sharing real time
data, across various clinical settings to enhance clinic decisions

24. 24
Cellgen Diagnostics: Intelligent Therapeutic Guidance Platform
Cellgen’s companion diagnostics platform will provide 2 outputs:
A Yes or No answer for a patient/drug genetic match decision
If yes, a predictive therapeutic outcome value
»» Cellgen will quantify a signature of miRNA expression levels and place those expression levels into a set of machine
learning algorithms that will classify the patients likely response to the given medicine. With every new patient, the
deep learning algorithms more specifically predict the therapeutic outcome of each patient.
Enhancing clinical decisions with machine learning

25. 25
Companion Diagnostics Success
Zelboraf (Vemurafenib)
Therapy for patients with metastatic
melanoma
Targets BRAF V600E mutation which exists in
50-60% of melanomas
In 2006, Plexxikon and Roche Molecular began
collaborating on development of a companion
diagnostic
Therapy and companion diagnostic approved in
2011, just 4 months after FDA submission and
only 5 years after the initial IND filing
Xalkori (Crizotinib)
Therapy for patients with non-small-cell lung
cancer
Targets ALK gene rearrangements which occur in
3-5% of patients
In 2009, Pfizer and Abbott Molecular began
collaborating on development of a companion
diagnostic
Therapy and companion diagnostic approved in
2011, just 5 months after FDA submission and only
1 year after being granted fast track designation by
FDA
Industry-leading Pharma Companies Are Embracing CDx

26. 26
An Immense Opportunity
Key Drivers
Advanced technologies increasing the adoption of companion diagnostics
Encouragement/requirements by regulatory bodies for companion diagnostics
Increasing costs of traditional drug discovery
Obvious benefits of companion diagnostics to all stakeholders
The global companion diagnostics market is expected to grow
at a 22.7% CAGR reaching $8.7 billion by 2019 Source: MarketsandMarkets
$8.7B
In 2019
~$4B
Now
“Companion Similar” Market Strategy
Target (or duplicate) established EGFR-related companion diagnostic tests which is
already a significant market opportunity
De-risk venture by removing lengthy and expensive biology clinical trials
Simply validate proven EGFR Biomarkers on Cellgen platform

27. 27
Cellgen Killer App: EGFR-related Cancer Companion Diagnostics
EGFR is a gene mutation that is used as a therapeutic
response indicator for various cancers, particularly
lung cancer
Epidermal Growth Factor Receptors (EGFR) mutations
are a common target of MANY drugs across various
cancer types, making EGFR the “killer” first piece of
content for Cellgen’s novel EVAP platform
Focusing on existing EGFR-related CDx tests addresses
a signifcant slice of the $8.7B projected CDx testing
market
Cellgen is in the process of developing and validating a
menu of EGFR CDx tests to launch commercial LDTs
Clear visibility to a robust menu of companion diagnostics content
Lung
Head
Neck
Immuno Therapy
(Future)
Colon
Pancreatic
Thyroid
Breast
Other

28. 28
A Winning Combination
Near-Patient
Capabilities
Yes None None None
Size Small Medium Large Large
Scope of Services Full Full Full Full
One Stop Shop Yes Yes Yes Yes
IVD/LDT IVD LDT LDT LDT
Preferred Sample Type Biofluids Biofluids Tissue Tissue
Target Flexibility
Many (DNA, RNA, Protein,
Exosomes)
Limited by technology
systems adopted
Limited Limited
Test Turnaround Time 5 hours 7-10 days 7-10 days 7-10 days
Cellgen combines the best characteristics of a leading CDx partner with a
proprietary POCT platform empowering clinician preference and increased
drug throughput

29. 29
The Path Forward
Cellgen will follow a well established path to successfully
comercialize its groundbreaking EVAP Clinical CDx platform
Phase 1
(1-12 months):
Develop prototype
open CLIA lab
Phase 2
(12-24 months):
Partner of choice for
pharma and research
labs
Phase 3
(24-36 months):
Generate revenue
from trials and
research as LDTs
Phase 4
(month 36):
Begin FDA approval
process

30. 30
Strong Ongoing Collaborations Validate Our Solution
Plan to use of Cellgen’s EVAP
technology to validate assays
related to
Protein Detection
Bacterial Detection
Using Cellgen’s EVAP
technology to validate assays
across a diverse set of
infectious disease targets
Bio terror
Infectious disease
Livestock
Agricultural
Veterinary
Food safety
Environmental
Promising discussions
regarding miRNA
applications of Cellgen’s
EVAP technology
Lung cancer
Breast cancer
Colon cancer
Glioblastoma
Lymphoma leukemia

31. 31
Market Applications: Beyond Human Healthcare
Although Cellgen is focused on cancer markets, potential acquirers will be
attracted to its combination of full automation and diverse target detection
capabilities (DNAs, RNAs Proteins) perfectly suited for large and growing
markets outside of healthcare
A key component to
delivering the many
promises of personalized
medicine. Key indications
include: depression, asthma,
cystic fibrosis, HIV.
Allows for in-field testing
of various agricultural and
animal products
Rapid, on-site testing for
various harmful biological
and environmental agents
A simple system to power a broad
array of life science research
Healthcare Biothreat
Environmental
Food Safety
Agriculture
Basic Research

32. Lavance Northington
Chief Executive
lavance@CellgenDx.com
949-285-6888
Thank you